Vaxart, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.51 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.78, a 0.00% change year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.78.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.31, a 75.00% decline from fiscal 2022.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.24, a 23.93% decline from fiscal 2021.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.63, a 12.41% increase from fiscal 2020.
- Vaxart, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $1.45.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.51 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $0.00 S-1 · filed 2026-05-08 | |||
| 2025-12-31 | $0.78 S-1 · filed 2026-05-08 | |||
| 2025-09-30 | $0.78 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.78 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $0.78 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $0.78 S-1 · filed 2026-05-08 | |||
| 2024-09-30 | $0.78 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $0.78 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.78 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $0.31 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $0.31 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $0.31 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $1.24 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $1.28 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $1.11 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $1.57 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $1.63 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $1.61 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $1.56 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $1.11 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $1.45 10-K · filed 2022-02-24 | |||
| 2020-09-30 | $1.32 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.65 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $0.77 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $6.49 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $6.49 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $6.49 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $6.49 10-Q · filed 2018-05-15 | |||
| 2017-12-31 | $8.58 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |